Clinical trial · no report yet · Phase 2
EVENET
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
- NCT06472388 ↗
- Recruiting
- AC Camargo Cancer Center
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Everolimus 5 mg vs 10 mg/Daily for Patients With Advanced Neuroendocrine Tumors
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Neuroendocrine Tumors; Progression; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Carcinoid
- Interventions
- Everolimus 5 MG
- Arms
- Everolimus 5 · Experimental
- Everolimus 10 · Active comparator
- Enrollment
- 100 (estimated)
- Primary outcomes
- Progression free survival rate at 12 months
- Sponsor
- AC Camargo Cancer Center
- Start
- Apr 24, 2024
- Primary completion
- May 20, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06472388 · updated Jun 25, 2024